All Videos

Sanjay Konagurthu of Thermo Fisher Scientific discusses how AI and ML can help solve the dilemma of poor solubility.

To meet rising demand, developers of precision radiopharmaceutical therapies must overcome challenges in global isotope supply and align R&D platforms with evolving FDA guidance on clinical dosimetry.

Mechanistic models and hypothesis-driven strategies generate optimized efficient solutions for drug development, says Catalent’s Nathan Bennette at AAPS PharmSci 360.

Accelerated drug development insights using AI/digital twins, advanced bioanalysis, targeted delivery, and optimized formulation stability models.

To prevent catastrophic loss of expertise and investment, government and academic leaders say coordinated policy and significant investment in workforce talent are urgently needed in the UK.

At AAPS PharmSci 360 2025, Elly Zhou says digital twins helped forecast the effects of drugs on human drugs via a digital control arm.

Siddhant Sojitra, Alexion, defines in an AAPS PharmSci 360 2025 presentation an agitation model to reliably test stability for early-stage biologics.

Pharmaceutical Technology® spoke with Steve Lowes, senior director of Scientific Affairs at IQVIA Laboratories, ahead of AAPS PharmSci 360 to discuss some of the unique instruments used to conduct bioanalysis.

Pharmaceutical Technology® spoke with Steve Lowes, senior director of Scientific Affairs at IQVIA Laboratories, ahead of AAPS PharmSci 360 to discuss method validation of biomarker bioanalysis.

Long Yuan, PhD, director of the Department of Drug Metabolism and Pharmacokinetics at Biogen, provides a look into some of the trends impacting bioanalysis in biopharmaceutical development and manufacturing.

AI is transforming pharma R&D, bioanalysis, and manufacturing. The industry faces intense competition (obesity wars) and FDA regulatory instability.

Pharmaceutical Technology® spoke with Steve Lowes, senior director of Scientific Affairs at IQVIA Laboratories, ahead of AAPS PharmSci 360 to discuss how LC–MS is used in bioanalysis.

Long Yuan, PhD, director of the Department of Drug Metabolism and Pharmacokinetics at Biogen, explains how artificial intelligence, machine learning, and large language models are used in performing bioanalysis.

AAPS PharmSci 360 will spotlight AI advances, gene therapy progress, and leading pharma research insights this year, says programming chair Mei He.

Thermo Fisher’s Jennifer Cannon reviews the first year of the company’s Accelerator Drug Development suite of services and the overall experience of attending the CPHI conference.

Frank Romanski of Lonza Capsugel dives into the excipient side of manufacturing and the emerging prevalence of digitalization.

In Episode 28, Miroslav Gasparek, Sensible; Lizzy Lawrence, STAT; and Joe Lewis, Deloitte, go behind the headlines.

Exclusive interviews revealed that digital transformation, data integrity protocols, and a regionalized supply chain are crucial strategies for optimizing drug development and manufacturing efficiency.

The planned Kenvue acquisition, expected to close in the second half of 2026, has notable implications for pharmaceutical R&D and manufacturing professionals.

J.D. Mowery, Bora, says global sustainability standards are good, AI implementation demands data cleansing, and outsourcing must mature.

Patient compliance is driving the emergence of new modalities, as Frank Romanski of Lonza Capsugel explains in the first installment of a two-part discussion.

AI-driven pharma trends: R&D acceleration via data integration, supply chain localization, excipient innovation, and rapid workforce upskilling.

In this episode of Drug Digest, the discussion centers around the optimization of biopharmaceutical manufacturing and supply chain efficiency through the mastering of AI capabilities, data integration, and critical validation challenges.

J.D. Mowery, Bora, says tariffs localize biopharma supply chains, the "biotech freeze" mandates robust data, and AI rapidly optimizes operations.

Maggie Saykali, Cefic, explains that Western pharma vulnerability stems from market loss to Asia, caused largely by short-sighted offshoring due to environmental costs.

Nigel Langley of gChem stresses excipient innovation, safer solvents, and supply chain resilience for pharma’s future in part 2 of a 2-part interview related to his presentation at CPHI Europe 2025.

Eva-Maria Hempe, NVIDIA, says AI collaboration optimizes life science research via routine automation, freeing human experts for complex strategy, ethics, and exploring scarce data.

As Thermo Fisher’s Jennifer Cannon explains in this first part of a two-part interview, the collaboration is intended to help improve the speed and success of drug development.

Pharmaceutical Technology® spoke with Peter Freed, head of Global Pharma CTS, Roquette, about a variety of materials-related topics including protein stability, tablet coating, sustainability, and securing the supply chain.

Maggie Saykali, Cefic, emphasizes the importance of competitiveness and innovation for European manufacturers to create added value and maintain environmental standards.